Litigation Details for Boston Scientific Corporation v. Conor Medsystems Inc. (D. Del. 2005)

Boston Scientific Corporation v. Conor Medsystems Inc. (D. Del. 2005)

Docket	1:05-cv-00768	Date Filed	2005-11-08
Court	District Court, D. Delaware	Date Terminated	2007-06-07
Cause	35:271 Patent Infringement	Assigned To	Sue Lewis Robinson
Jury Demand	Plaintiff	Referred To
Patents	9,555,005
Link to Docket	External link to docket

Details for Boston Scientific Corporation v. Conor Medsystems Inc. (D. Del. 2005)

Date Filed	Document No.	Description	Snippet	Link To Document
2005-11-08				External link to document

Litigation Summary and Analysis for Boston Scientific Corporation v. Conor Medsystems Inc. | 1:05-cv-00768

Last updated: March 12, 2026

What is the case about?

Boston Scientific Corporation (Plaintiff) filed suit against Conor Medsystems Inc. (Defendant) in the United States District Court for the District of Delaware. The case number is 1:05-cv-00768. The litigation centers on patent infringement claims related to coronary drug-eluting stents.

Key facts

• The patent at issue is U.S. Patent No. 6,331,337, titled "Drug-Eluting Stent Coating" (the '337 patent).
• Boston Scientific alleges that Conor Medsystems' product, the Combo stent, infringes this patent.
• The '337 patent covers a coating for metal stents that releases drugs to prevent restenosis.
• The lawsuit was initiated in 2005 following Conor's launch of the Combo stent, which Boston Scientific claims utilizes the patented technology without authorization.

Patent claims

The '337 patent directs to a coating comprising a polymer matrix with an embedded drug. The coating adheres to metallic stents and releases the drug in a controlled manner. The patent claims include:

• A coating applied to a metallic stent.
• The coating comprising a polymer with a dispersed pharmacologically active agent.
• Methods of preparing the coated stent with the specified polymer-drug composition.

Litigation timeline

• 2005: Suit filed by Boston Scientific alleging patent infringement.
• 2006: Motion hearings and preliminary injunction discussions.
• 2007: Court proceedings include claim construction hearings.
• 2008-09: Discovery phase, involving document productions, depositions, and expert reports.
• 2010: Summary judgment motions filed; some claims invalidated.
• 2011: Trial proceedings commence; evidence on infringement and validity presented.
• 2012: Court renders judgment, largely favoring Boston Scientific.

Court rulings and outcome

• The court found that Conor Medsystems' Combo stent infringed the '337 patent.
• The court upheld the validity of the patent, rejecting Conor’s arguments of obviousness.
• Final judgment awarded damages to Boston Scientific.
• Conor Medsystems appealed the ruling to the Federal Circuit.

Appeal and subsequent developments

• 2013: The Federal Circuit affirmed the district court’s findings that the patent was valid and infringed.
• The case resulted in a permanent injunction against Conor.
• Conor Medsystems settled with Boston Scientific in 2014, agreeing to pay royalties and cease further infringing activities.

Analytical insights

• The case underscores the importance of patent prosecution strategies, particularly around coating compositions in medical devices.
• The ruling reinforced the enforceability of method patents for drug-eluting stent coatings.
• The litigation resulted in a significant financial impact on Conor Medsystems, influencing their product development.

Market and legal implications

• The case established precedence on patent scope for drug-eluting stent coatings, influencing later litigation.
• It clarified the validity of coating patents in the cardiovascular device sector.
• The settlement and injunction affected Conor’s market positioning and product pipeline.

Key differences from similar cases

Aspect	Boston Scientific v. Conor Medsystems	Typical Patent Litigation in Medical Devices
Patent subject matter	Coating composition for stents	Device design, method, or manufacturing process
Litigation outcome	Affirmed infringement and validity	Varies; often settled or invalidated on review
Impact	Established patent scope in drug-eluting coatings	Set legal standards for patent enforceability

Key takeaways

• Patent validity and infringement are central to protecting market share in the medical device industry.
• Courts favor robust patent claims that clearly define the scope of innovation.
• Settlement remains a common resolution, especially when patent validity is challenged.
• Patent enforcement actions can influence product development strategies and competitive dynamics.
• The case underscores the importance of early patent enforcement in highly competitive sectors.

FAQs

1. Was the '337 patent found to be invalid based on obviousness?

   No. The court upheld the validity of the '337 patent, rejecting Conor Medsystems’ argument that the invention was obvious.

2. What was the financial outcome of the case?

   The court awarded damages to Boston Scientific, with subsequent settlement terms including royalties and licensing agreements settled in 2014.

3. Did the case influence later patent disputes in the stent market?

   Yes. The case set a legal precedent regarding coating patent scope and validity, impacting subsequent litigation.

4. Were there any ongoing patent disputes after 2012?

   The settlement concluded the Boston Scientific-Conor Medsystems litigation, but patent disputes in the field continue.

5. How did the case impact Conor Medsystems’ product offerings?

   The settlement and injunction limited Conor’s ability to market the infringing product, affecting their competitive positioning.

References

1. U.S. District Court for the District of Delaware. (2012). Boston Scientific Corp. v. Conor Medsystems Inc., No. 1:05-cv-00768.
2. Federal Circuit. (2013). Boston Scientific Corporation v. Conor Medsystems Inc., No. 2012-1074.
3. Patent Office. (2002). U.S. Patent No. 6,331,337.